Alumis (NASDAQ:ALMS) Sets New 12-Month High – What’s Next?

Alumis Inc. (NASDAQ:ALMS) reached a new 52-week high during trading on Tuesday . The company traded as high as $22.30 and last traded at $18.8590, with a volume of 30153270 shares trading hands. The stock had previously closed at $8.31.

More Alumis News

Here are the key news stories impacting Alumis this week:

• Positive Sentiment: Phase 3 success — Both ONWARD trials met all primary and secondary endpoints with high statistical significance; strong efficacy (PASI‑90 ~65%, PASI‑100 >40% at Week 24) and tolerability support a planned NDA H2 2026. GlobeNewswire Release
• Positive Sentiment: Strong market reaction — The clinical news triggered heavy intraday volume and a large price move, reflecting investor reassessment of ALMS’s commercial and valuation prospects. Benzinga
• Positive Sentiment: Competitive positioning — Company statements and media coverage position envudeucitinib as a leading next‑generation oral therapy in plaque psoriasis, potentially challenging larger incumbents. Schaeffer’s Research
• Neutral Sentiment: Conference call & webcast — Management hosted a conference call/webcast to discuss topline data and will post a replay; investors should listen for subgroup data, safety details and regulatory timeline color. QuiverQuant
• Neutral Sentiment: News flow confirmation — Major outlets (Reuters, Business Insider, TipRanks) corroborated the topline results; expect follow‑up releases with full data and peer comparisons. Reuters
• Negative Sentiment: Execution & regulatory risk remains — NDA filing targeted H2 2026 but approval is not guaranteed; full datasets, long‑term safety, and label/commercial positioning will determine ultimate value.
• Negative Sentiment: Financials & valuation risk — Alumis remains a pre‑commercial, unprofitable company with recent quarterly revenue and EPS misses; a successful approval still requires scaling commercialization and justifying current market cap.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on ALMS shares. Wells Fargo & Company reissued an “overweight” rating on shares of Alumis in a report on Tuesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alumis in a research note on Monday, December 29th. HC Wainwright lifted their target price on Alumis from $14.00 to $20.00 and gave the company a “buy” rating in a research note on Thursday, December 18th. Finally, Wall Street Zen raised Alumis from a “sell” rating to a “hold” rating in a report on Saturday, December 6th. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $20.40.

Alumis Stock Performance

The company has a market capitalization of $1.80 billion, a PE ratio of -4.28 and a beta of -2.09. The firm’s 50-day simple moving average is $8.16 and its 200 day simple moving average is $5.53.

Alumis (NASDAQ:ALMS) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($1.06) EPS for the quarter, missing the consensus estimate of ($0.92) by ($0.14). The company had revenue of $2.07 million for the quarter, compared to analysts’ expectations of $3.14 million. As a group, equities analysts anticipate that Alumis Inc. will post -8.51 earnings per share for the current year.

Insider Activity

In other news, Director Srinivas Akkaraju acquired 186,377 shares of the company’s stock in a transaction that occurred on Friday, December 5th. The stock was purchased at an average cost of $9.84 per share, with a total value of $1,833,949.68. Following the purchase, the director directly owned 1,265,253 shares of the company’s stock, valued at approximately $12,450,089.52. This trade represents a 17.28% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Also, major shareholder Foresite Capital Management Vi acquired 190,500 shares of Alumis stock in a transaction that occurred on Wednesday, November 19th. The shares were purchased at an average cost of $6.56 per share, with a total value of $1,249,680.00. Following the completion of the acquisition, the insider owned 2,542,003 shares of the company’s stock, valued at $16,675,539.68. The trade was a 8.10% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders purchased 2,788,875 shares of company stock worth $18,352,357. Company insiders own 40.70% of the company’s stock.

Institutional Trading of Alumis

Several large investors have recently bought and sold shares of ALMS. Russell Investments Group Ltd. raised its stake in shares of Alumis by 320.9% during the 3rd quarter. Russell Investments Group Ltd. now owns 6,419 shares of the company’s stock worth $26,000 after buying an additional 4,894 shares during the last quarter. CWM LLC increased its holdings in Alumis by 1,028.7% during the 3rd quarter. CWM LLC now owns 10,384 shares of the company’s stock valued at $41,000 after acquiring an additional 9,464 shares in the last quarter. Kera Capital Partners Inc. acquired a new position in Alumis during the second quarter worth about $32,000. Corebridge Financial Inc. raised its position in Alumis by 53.0% during the first quarter. Corebridge Financial Inc. now owns 10,658 shares of the company’s stock worth $65,000 after acquiring an additional 3,693 shares during the last quarter. Finally, Police & Firemen s Retirement System of New Jersey lifted its holdings in shares of Alumis by 199.7% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 10,753 shares of the company’s stock valued at $32,000 after purchasing an additional 7,165 shares in the last quarter.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.